Article
Circulating tumor DNA predicts efficacy of a dual AKT/p70S6K inhibitor (LY2780301) plus paclitaxel in metastatic breast cancer: plasma analysis of the TAKTIC phase IB/II study.
Molecular oncology - 1 May 2022
Sabatier Renaud, Vicier Cécile, Garnier Séverine, Guille Arnaud, Carbuccia Nadine, Isambert Nicolas, Dalenc Florence, Robert Marie, Levy Christelle, Pakradouni Jihane, Adelaïde José, Chaffanet Max, Sfumato Patrick, Mamessier Emilie, Bertucci François, Goncalves Anthony
Abstract excerpt
The phosphatidylinositol-3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway is frequently activated in HER2-negative breast cancer and may play a role in taxane resistance. The phase IB/II TAKTIC trial (NCT01980277) has shown that combining a dual AKT and p70 ribosomal protein S6 kinase (p70S6K) inhibitor (LY2780301) taken orally with weekly paclitaxel in HER2-negative advanced breast cancer is...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.